Lts Lohmann Therapie-systeme Ag

Lts Lohmann Therapie-systeme Gmbh

Other

Lts Lohmann Therapie-systeme Gmbh + Co. Kg

Lts Lohmann Therapie Systeme Gmbh & Co.

Purdue Pharma L.p.

Klinge Pharma Gmbh

National Starch and Chemical Investment Holding Corporation

Israel Institute for Biological Research

Hf Arzneimittelforschung Gmbh

Lts Lohman Therapie-systeme Gmbh & Co. Kg

Paul Hartmann Ag

Thomas Hille

Lothar Deurer

Hans-Rainer Hoffmann

Bodo Asmussen

Gabriel Wauer

Rudolf Matusch

Peter Steinborn

Klaus Opitz

Mirko Kreh

Petra Botzem

Walter Müller

Frank Seibertz

Ludwig Grader

Fritz Stanislaus

Michael Horstmann

Walter Muller

Klaus Schumann

Dieter Anhauser

Walter Mueller

Gerhard Schneider

Hans-Joachim Huber

Marlene Fuhrmann

Karlheinz Otto

Gerhard Ritzdorf

Paul B Foreman

Andreas Koch

Frank Becher

Paul M Petersen

Kevin John Smith

Robert-Peter Klein

Fritz Herrmann

Heiko Spilgies

Andreas Henning

Rolf Pracht

Frank Theobald

Thomas Profitlich

James Burkert

Joachim Moormann

Torsten Grunenberg

Kersten Walter

Axel Knoch

Margit Wirz

Werner Wessling

Gerd Ritzdorf

Axel Koch

Helena Gallinger

Aharon Levy

Yacov Meshulam

Hans-Werner Wolf

Shu-Lun Weinheimer

Bernhard Hehn

Helen Elizabeth Johnson

Gillian Elizabeth Mundin

Robert-Peter (deceased) Klein

The invention relates to a microneedle array, in particular to an applicator system, and to the use thereof for the intradermal delivery of active ingredients in the form of salts, in particular medicinal drugs in the form of salts, wherein this microneedle array is suitable for penetrating the skin of humans or animals, and the microneedles are made of a formulation, containing at least one active ingredient in the form of a salt and at least one biodegradable polymer.

Microneedle array having an active ingredient in the form of salts

Disclosed are stable dosage forms for oral administration of active pharmaceutical ingredients in which any unpleasant taste sensation, caused by release of the active pharmaceutical ingredient and/or of the excipients in the oral and pharyngeal cavity of the patient, is masked by the use of theobromine-free cocoa.

Oral dosage form containing theobromine-free cocoa

The invention relates to transparent therapeutic systems (TTS) which contain the active substance nicotine and which further contain at least one acid amide group as a lateral functional group. The TTS can be transparent and for discreet use. The invention also relates to methods for producing these TTS, said TTS being produced by methods using said polymers and being charged with active substance by way of a printing method.

Nicotine-containing transparent transdermal therapeutic system

Disclosed is a method for marking film-type dosage forms, comprising at least the positioning of a film-type dosage form between two layers of a sealable packaging material, the sectional heat-sealing of the two layers of the sealable packaging material so as to obtain an edge-sealed bag containing the film-type dosage form, and the blind-embossing of the film-type dosage form contained in the edge-sealed bag through at least one of the two layers of packaging material of the edge-sealed bag.

Method of marking film-like dosage forms

The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment () and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer () and an adhesive polymer layer () that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layersand

Over-patch having improved compatibility and a long adhesion duration and method for producing said over-patch

A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance. This mixture forms dispersed deposits in the pressure-sensitive adhesive. The buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.

Buprenorphine transdermal delivery system

The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Transdermal therapeutic system with fentanyl or related substances

The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterised in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time.

Transdermal therapeutic system having improved long-term wearing comfort

The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising

Transdermal delivery system comprising buprenorphine

The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerably increased utilization of the active substance.

Transdermal therapeutic system for administering the active substance buprenorphine

Buprenorphine transdermal therapeutic system and method of administering

The invention relates to a transdermal therapeutic system which comprises a back layer that is impermeable to the active substance, and a peelable protective layer that is impermeable to the active substance and at least one matrix layer consisting of polysiloxanes and/or polysiloxane derivatives and containing micro-reservoirs. Said micro-reservoirs contain at least one ion pair from a pharmacologically active substance and an additive and either the active substance is nucleophilic and the additive is electrophilic or the active substance is electrophilic and the additive is nucleophilic.

Transdermal therapeutic system comprising ion pair microreservoirs

Growing community of inventors

Neuwied, Germany

Thomas Hille